Online inquiry

IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2502MR)

This product GTTS-WQ2502MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&FOLH1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001014986.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 2346
UniProt ID P07766; Q04609
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ2502MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14976MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SHR-1314
GTTS-WQ7732MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ9551MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ1458MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ9165MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ2661MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ8732MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ1529MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW